Background
Patients and methods
Patients
Patient-reported outcome assessments
Statistical analysis
Results
Patients
TCZ-QW + Pred-26 N = 100 | PBO + Pred-26 N = 50 | PBO + Pred-52 N = 51 | |
---|---|---|---|
Age, years | 69.5 (8.5) | 69.3 (8.1) | 67.8 (7.7) |
Female, n (%) | 78 (78.0) | 38 (76.0) | 37 (72.5) |
Race, n (%) | |||
White | 97 (97.0) | 50 (100.0) | 49 (96.1) |
Black or African American | 1 (1.0) | 0 | 2 (3.9) |
Asian | 0 | 0 | 0 |
Other | 1 (1.0) | 0 | 0 |
Unknown | 1 (1.0) | 0 | 0 |
Weight, kg | 69.8 (13.8) | 70.1 (15.8) | 73.1 (15.3) |
Disease duration, days | 306.8 (563.5) | 364.7 (569.9) | 255.2 (435.5) |
Disease onset, n (%) | |||
Newly diagnosed | 47 (47.0) | 23 (46.0) | 23 (45.1) |
Relapsing | 53 (53.0) | 27 (54.0) | 28 (54.9) |
Prednisone dose, mg/day | 34.6 (13.4) | 34.6 (13.0) | 34.5 (14.2) |
Cranial signs or symptoms, n (%) | 41 (41.0) | 20 (40.0) | 16 (31.4) |
PMR symptoms | 59 (59.0) | 30 (60.0) | 35 (68.6) |
ESR, mm/h | 24.6 (18.7) | 28.8 (25.4) | 24.2 (18.2) |
SF-36 PCS | 43.1 (9.4) | 42.6 (10.9) | 41.1 (10.0) |
SF-36 MCS | 42.8 (12.4) | 42.7 (12.1) | 40.5 (13.7) |
FACIT-Fatigue | 36.1 (11.1) | 35.0 (12.8) | 31.4 (13.6) |
PtGA, 100 mm VAS | 43.6 (25.7) | 35.7 (28.2) | 47.8 (27.8) |
SF-36
SF-36 PCS | SF-36 MCS | |||||
---|---|---|---|---|---|---|
TCZ-QW + Pred-26 N = 100 | PBO + Pred-26 N = 50 | PBO + Pred-52 N = 51 | TCZ-QW + Pred-26 N = 100 | PBO + Pred-26 N = 50 | PBO + Pred-52 N = 51 | |
Baseline | 43.10 n = 97 | 42.65 n = 48 | 41.12 n = 49 | 42.77 n = 97 | 42.73 n = 48 | 40.45 n = 49 |
Week 52 | 47.75 n = 85 | 41.52 n = 43 | 41.24 n = 45 | 51.64 n = 85 | 49.36 n = 43 | 44.86 n = 45 |
LSM change from baseline to week 52 | 4.18*† n = 95 | − 0.98 n = 47 | − 0.40 n = 49 | 8.10†‡ n = 95 | 5.25† n = 47 | 1.89 n = 49 |
A/G norms | TCZ-QW + Pred-26 N = 100 | PBO + Pred-26 N = 50 | PBO + Pred-52 N = 51 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
p value | p value | |||||||||||
BL | Wk 52 | LSM Δ BL–Wk 52 | BL | Wk 52 | LSM Δ BL–Wk 52 | TCZ-QW + Pred-26 vs PBO + Pred-26 | BL | Wk 52 | LSM Δ BL–Wk 52 | pTCZ-QW + Pred-26 vs PBO + Pred-52 | ||
PF | 67.56 | 69.10 n = 100 | 78.28 n = 85 |
6.83
n = 98 | 63.60 n = 50 | 63.48 n = 43 | − 3.43 n = 49 | 0.0024 | 59.40 n = 50 | 65.44 n = 45 | 2.68 n = 50 | NS |
RP | 69.44 | 49.56 n = 100 | 73.75 n = 85 |
20.64
n = 98 | 52.42 n = 49 | 58.28 n = 43 |
5.87
n = 48 | < 0.001 | 45.38 n = 50 | 53.89 n = 45 | 4.46 n = 50 | < 0.001 |
BP | 64.52 | 61.93 n = 100 | 73.25 n = 85 |
10.89
n = 98 | 58.90 n = 50 | 61.77 n = 43 | 1.00 n = 49 | NS | 55.67 n = 49 | 56.27 n = 45 | − 2.87 n = 49 | < 0.001 |
GH | 66.49 | 55.00 n = 97 | 65.81 n = 85 |
9.06
n = 95 | 56.43 n = 49 | 57.28 n = 43 | − 1.34 n = 48 | < 0.001 | 55.69 n = 50 | 52.29 n = 45 | − 4.05 n = 50 | < 0.001 |
VT | 58.65 | 50.19 n = 99 | 66.13 n = 85 |
15.69
n = 97 | 49.00 n = 50 | 55.67 n = 43 |
5.26
n = 49 | 0.0011 | 42.38 n = 50 | 49.17 n = 45 | 3.53 n = 50 | < 0.001 |
SF | 81.49 | 64.25 n = 100 | 84.71 n = 85 |
17.35
n = 98 | 65.25 n = 50 | 75.87 n = 43 |
9.83
n = 49 | NS | 63.00 n = 50 | 67.50 n = 45 | 2.34 n = 50 | < 0.001 |
RE | 82.08 | 66.38 n = 100 | 82.45 n = 85 |
13.37
n = 98 | 64.63 n = 49 | 74.81 n = 43 |
6.44
n = 48 | NS | 60.33 n = 50 | 69.63 n = 45 | 3.53 n = 50 | NS |
MH | 77.16 | 64.04 n = 99 | 77.94 n = 85 |
12.54
n = 97 | 64.20 n = 50 | 73.60 n = 43 |
7.43
n = 49 | NS | 59.10 n = 50 | 66.33 n = 45 | 3.13 n = 50 | < 0.001 |
SF-6D utility score | 0.746 | 0.694 | 0.775 |
0.080
| 0.686 | 0.721 | 0.034 | – | 0.663 | 0.692 | 0.029 | – |